TABLE 2.
Outcomes
| Variables | Developed Hypertriglyceridemia (n = 38) | Did Not Develop Hypertriglyceridemia (n = 98) | p |
|---|---|---|---|
| Days in ICU (hr)a | 14 (8.3–25) | 8.5 (5–14) | 0.0015 |
| Duration of propofol administration (hr)a | 112.5 (72–192) | 64.5 (34–132.8) | 0.0008 |
| Total daily propofol dose (g)a | 3.5 (2.6–5.2) | 2.8 (1.5–4.2) | 0.0048 |
| Total cumulative propofol dose (g)a | 21.8 (9.3–32.4) | 12 (4.4–19.3) | 0.016 |
| Propofol discontinued due to hypertriglyceridemia, n (%) | 24 (63.2) | — | — |
| Propofol rate at the time of development hypertriglyceridemia (µg/kg/min)a | 50 (30.3–63.8) | — | — |
| Time to develop hypertriglyceridemia (hr)a | 47 (16.3–73.5) | — | — |
| Average rate during first 48 hr (µg/kg/min), n (%) | 37.1 | 28.4 | 0.264 |
| Development of pancreatitis, n (%) | 2 (5.3) | 0 | 0.083 |
| Median daily triglyceride level (mg/dL)a | 359.5 (297–549) | 145.5 (106-199) | 0.0001 |
| Patients with triglyceride level > 1,000 mg/dL, n (%) | 10 (26.3) | — | — |
| Peak triglyceride level (mg/dL)a | 605 (486–999.5) | 168.5 (108.8-239) | 0.001 |
| Triglyceride level at development of hypertriglyceridemia (mg/dL)a | 499 (438–679.8) | — | — |
| Average lipase level (U/L)a | 33 (22.5–110) | 31.5 (17.8-52.9) | 0.114 |
aData presented as median (interquartile range).
Dashes indicate no p value to compute and data point did not apply to group that did not develop hypertriglyceridemia.